[1] Yang Y,Im SA,Kim TY,et al.Abstract P3-11-15:Different clinical usefulness of AJCC response criteria according to the subtypes in stage Ⅱ/Ⅲ breast cancer patients after neoadjuvant chemotherapy[J].Cancer Res,2015,75(9):11-15.
[2] Wolmark N,Mamounas EP,Baehner FL,et al.Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen:results from NRG Oncology/National Surgical Adjuvant Breast and Bowel project B-28 and B-14[J].J Clin Oncol,2016,34(20):2350-2358.
[3] Khoja L,Lorigan P,Dive C,et al.Circulating tumour cells as tumour biomarkers in melanoma:detection methods and clinical relevance[J].Ann Oncol,2015,26(1):33-39.
[4] Zhao S,Yang H,Zhang M,et al.Circulating tumor cells (CTCs) detected by triple-marker EpCAM,CK19,and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients[J].Cell Biochem Biophys,2013,65(2):263-273.
[5] Yamamoto H,Murata K,Fukunaga M,et al.Micrometastasis volume in lymph nodes determines disease recurrence rate of stage Ⅱ colorectal cancer:a prospective multicenter trial[J].Clin Cancer Res,2016,22(13):3201-3208.
[6] Ma LX,Cai QY,Yu P,et al.Specific detection of circulating tumor cells in peripheral blood by targeting gastrin releasing peptide receptors[J].J Nucl Med,2016,57(9):1220.
[7] Chia NY,Tan P.Molecular classification of gastric cancer[J].Ann Oncol,2016,27(5):763-769.
[8] Sargent DJ,Shi Q,Gill S,et al.Molecular testing for lymph node metastases as a determinant of colon cancer recurrence:results from a retrospective multicenter study[J].Clin Cancer Res,2014,20(16):4361-4369.
[9] McCall MN,Almudevar A.Affymetrix GeneChip microarray preprocessing for multivariate analyses[J].Brief Bioinform,2012,13(5):536-546.
[10] Ting SL,Kwok SK,Tsang AHC,et al.The study on using passive RFID tags for indoor positioning[J].Int J Engineer Business Manag,2011,3(1):9-15.
[11] Pantel K.Detection,clinical relevance and specific biological properties of disseminating cancer cells in breast cancer patients[J].Cancer Res,2009,69(2):233-240.
[12] Qu YM,Liao GQ,Liu PH,et al.Clinical significance of expressions of tumor markers in peripheral blood in non-small cell lung cancer[J].Zhonghua Yi Xue Za Zhi,2010,90(28):1958-1962.
[13] Liu L,Ma C,Xu Q,et al,A rapid nested polymerase chain reaction method to detect circulating cancer cells in breast cancer patients using multiple marker genes[J].Oncol Lett,2014,7(6):2192-2198.
[14] Liu L,Xu Q,Cheng L,et al.NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients[J].Oncol Lett,2015,9(2):891-896.
[15] Ait-Mohand S,Dumulon-Perreault V,Benard F,et al.Design optimization of a new 64Cu/NOTA truncated NPY analog with improved stability and Y1 affinity,the first step toward successful breast cancer PET Imaging[J].J Nucl Med,2016,57(suppl 2):1076.
[16] Shi ZG,Brooks VL.Select inhibition of arcuate NPY/AgRP neurons increases arterial pressure and sympathetic nerve activity in mice[J].FASEB J,2016,30(suppl 1):1235-1236.
[17] Spencer B,Potkar R,Metcalf J,et al.Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease[J].J Biol Chem,2016,291(4):1905-1920. |